Newsroom | 4987 results

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the presentation of new preclinical data for elunetirom, the company’s lead asset currently in Phase 2 clinical development for adjunctive major depressive disorder (MDD) and bipolar depression, at the 64th Annual American College of Neuropsychopharmacology (ACNP) Annual Meeting taking place in Nassau...

OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (TSE:4528), today announced that Toichi Takino, President and COO, presented at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST. An audio recording of the event is available here and accessible until February 15, 2026. About Ono Pharmaceutical Co., Ltd. Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of “Dedic...

TORONTO--(BUSINESS WIRE)--In North America, 250,000 children are unable to walk due to central nervous system injuries or neurological conditions, such as cerebral palsy. An effective physical therapy for children with injuries or disabilities affecting their motor skills requires an innovative solution that can build muscle memory and stimulate neuroplasticity. With support from OBIO®, Hamilton Health Sciences’ (HHS) McMaster Children’s Hospital has a new tool, the Trexo Plus, designed by Miss...

GUILFORD, Conn.--(BUSINESS WIRE)--Prospective study is designed to evaluate the feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI....

ALAMEDA, Calif.--(BUSINESS WIRE)--An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation’s PRIMA implant is the first treatment in clinical trials to successfully restore functional vision to certain patients suffering from geographic atrophy (GA) due to age-related macular degeneration (AMD), a leading cause of blindness affecting more than 5 million people worldwide. The editorial, Behind the Science: Restoring Vision for Patients with AMD a...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. The patent protects a key aspect of ALTO-207 – the use of ondansetron to mitigate pramipexole-related side effec...

SAN FRANCISCO--(BUSINESS WIRE)--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Capitalizing on new launch momentum, the company will drive significant global regulatory expansions and market penetration across its pharmaceutical portfolio. High-value commercial products and an accelerating modality-rich pipeline across oncology, cardiology, neurology, and immunology have firmly...

CAMBRIDGE, England & EDINBURGH, Scotland--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research, today announced that it has secured $2.8 million (£2.1 million) in funding. The investment was led by US life sciences specialist BroadOak Capital Partners, with the company’s founding investor, the Roslin Foundation, also participating. The funding will accelerate Axol’s next phase of growth, sup...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's neurological and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. “2026 marks a pivotal year for Acadia as we advance our strategy built for sustained growth and pipeline advancement,” said Catherin...

BOSTON--(BUSINESS WIRE)--Neurable, the leader in noninvasive brain-computer interface (BCI) technology, and HP Inc.'s HyperX, a leading gaming brand, received industry recognition at CES 2026 for their collaboration on a first-of-its-kind gaming headset that integrates neurotechnology to help players level up their game play by optimizing focus and performance. The headset prototype was honored in several prominent CES roundups, including Tom's Guide's "Best of CES 2026," TechRadar's "Best Head...